FY2025 Earnings Forecast for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Stock analysts at Zacks Research reduced their FY2025 earnings estimates for Bruker in a research note issued on Tuesday, October 15th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $3.04 for the year, down from their previous estimate of $3.07. The consensus estimate for Bruker’s current full-year earnings is $2.61 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.95 EPS and FY2026 earnings at $3.63 EPS.

Several other equities research analysts have also recently weighed in on the company. The Goldman Sachs Group dropped their price objective on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a report on Tuesday, July 9th. Wolfe Research downgraded shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Wells Fargo & Company assumed coverage on shares of Bruker in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 target price for the company. Barclays initiated coverage on shares of Bruker in a research report on Tuesday. They set an “overweight” rating and a $75.00 price target on the stock. Finally, Citigroup lowered their price objective on shares of Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, July 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $80.82.

Bruker Stock Down 1.3 %

NASDAQ BRKR opened at $60.49 on Wednesday. Bruker has a 1 year low of $53.79 and a 1 year high of $94.86. The stock has a market capitalization of $8.79 billion, a PE ratio of 22.00, a PEG ratio of 2.52 and a beta of 1.18. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. The business’s 50-day moving average is $65.09 and its 200 day moving average is $69.37.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, meeting the consensus estimate of $0.52. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The business had revenue of $800.70 million during the quarter, compared to analysts’ expectations of $799.44 million. During the same quarter in the prior year, the company posted $0.50 EPS. The firm’s revenue for the quarter was up 17.4% compared to the same quarter last year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Shareholders of record on Monday, September 2nd were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date was Friday, August 30th. Bruker’s dividend payout ratio (DPR) is presently 7.27%.

Institutional Trading of Bruker

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Lifestyle Asset Management Inc. boosted its holdings in Bruker by 1.3% in the first quarter. Lifestyle Asset Management Inc. now owns 12,534 shares of the medical research company’s stock worth $1,177,000 after acquiring an additional 158 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Bruker by 20.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 165 shares during the last quarter. Securian Asset Management Inc. increased its stake in Bruker by 2.3% during the 2nd quarter. Securian Asset Management Inc. now owns 7,766 shares of the medical research company’s stock valued at $496,000 after purchasing an additional 175 shares in the last quarter. Park Place Capital Corp raised its holdings in Bruker by 19.4% in the first quarter. Park Place Capital Corp now owns 1,139 shares of the medical research company’s stock worth $107,000 after buying an additional 185 shares during the last quarter. Finally, Covestor Ltd lifted its stake in shares of Bruker by 139.1% in the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after buying an additional 210 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.